Clinical Trial Update: Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure [Phase 2]

View source ↗

Summary

This trial update reports termination of a Phase 2 study evaluating the safety and efficacy of ALT-711 (alagebrium) in chronic heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Alagebrium (alagebrium)

Snippet

Sponsor: Synvista Therapeutics, Inc | Conditions: Chronic Heart Failure | Phase 2 | Status: TERMINATED